Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 16/20 | 0.64 |
| ▸ | ABL1 | P00519 | 10/20 | 0.60 |
| ▸ | DDR2 | Q16832 | 10/20 | 0.60 |
| ▸ | BCR | P11274 | 6/20 | 0.60 |
| ▸ | ABL2 | P42684 | 3/20 | 0.59 |
| ▸ | KIT | P10721 | 6/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9611004 | 0.92 | ABL1 (0.61) | DDR1ABL1DDR2BCRABL2 | |
| SCHEMBL10265418 | 0.89 | ABL1 (0.66) | DDR1ABL1DDR2BCRABL2 | |
| SCHEMBL9611036 | 0.88 | ABL1 (0.75) | DDR1ABL1BCRABL2KIT | |
| SCHEMBL9611057 | 0.88 | ABL1 (0.67) | DDR1ABL1DDR2BCRABL2 | |
| SCHEMBL15871944 | 0.87 | ABL1 (0.64) | DDR1ABL1DDR2BCRABL2 | |
| SCHEMBL10268800 | 0.87 | ABL1 (0.64) | DDR1ABL1DDR2BCRABL2 | |
| SCHEMBL9611007 | 0.86 | ABL1 (0.64) | DDR1ABL1DDR2BCRABL2 | |
| SCHEMBL9610971 | 0.86 | ABL1 (0.62) | DDR1ABL1DDR2BCRABL2 | |
| SCHEMBL14642795 | 0.85 | ABL1 (0.63) | DDR1ABL1ABL2KIT | |
| SCHEMBL15473034 | 0.85 | DDR1 (0.58) | DDR1ABL1DDR2BCRABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | DDR1 4853/4885ABL1 110/4885DDR2 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.